Tesamorelin/ipamorelin 12mg/6mg explained: ratio, how the blend compares to 8mg vials, research benefits, dosing logic, and safety facts for lab studies.
Tesamorelin/ipamorelin 12mg/6mg is a research-grade peptide blend that combines 12 mg of tesamorelin with 6 mg of ipamorelin in one vial. Tesamorelin is a growth hormone–releasing hormone (GHRH) analog, and ipamorelin is a selective growth hormone secretagogue. Sold for laboratory research only, this blend is not an FDA-approved combination product for human use.
What the 12mg/6mg Ratio Actually Means
The label "12mg/6mg" describes the total peptide mass in the vial, not the amount in a single dose. A 12 mg/6 mg blend contains twice as much tesamorelin as ipamorelin, which gives it a 2:1 ratio.
Vendors sometimes write the same product as "tesamorelin ipamorelin 12mg 6mg" or list the two peptides separately on the certificate of analysis. The order matters: the first number is always tesamorelin, and the second is ipamorelin.
- Total peptide content: 18 mg per vial (12 mg plus 6 mg).
- Ratio: 2 parts tesamorelin to 1 part ipamorelin.
- Common fill: 18 mg total, sometimes sold with slight overfill.
This ratio is popular because tesamorelin has a shorter half-life and is often studied at higher milligram amounts than ipamorelin. Researchers who want mostly GHRH activity with a smaller ghrelin-mimetic component tend to choose a 2:1 blend.
How Tesamorelin and Ipamorelin Work
Tesamorelin and ipamorelin act on different receptors, which is why they are sometimes studied together.
| Peptide | Mechanism | Reported half-life | FDA status |
|---|---|---|---|
| Tesamorelin | Binds GHRH receptors in the pituitary | About 26–38 minutes | Approved as Egrifta for HIV-associated lipodystrophy |
| Ipamorelin | Activates the ghrelin receptor GHS-R1a | About 2 hours | Not approved for human use |
| CJC-1295 | GHRH analog with extended action | Minutes (no DAC) to days (with DAC) | Not approved for human use |
| 12mg/6mg blend | Combined GHRH and ghrelin-receptor activity | Not established | Not approved for human use |
Tesamorelin binds GHRH receptors and triggers growth hormone release. Ipamorelin mimics ghrelin at the GHS-R1a receptor and also stimulates GH release, but animal data suggest it causes less cortisol and prolactin release than older secretagogues.
When a GHRH analog and a ghrelin mimetic are combined, researchers hypothesize additive or synergistic GH pulses. That hypothesis comes from studies of separate peptides, not from controlled trials of the 12 mg/6 mg blend itself.
Reported Benefits in Research
Tesamorelin is the only peptide in this blend with large human trials behind it. In phase 3 studies of HIV-associated lipodystrophy, tesamorelin reduced visceral adipose tissue and improved trunk fat measures over 26 to 52 weeks.
Ipamorelin research is much earlier. Most published work uses animal models or small human studies focused on GH release, not on body composition or recovery outcomes.
People searching tesamorelin cjc1295 ipamorelin 12mg blend benefits usually want to know whether the combo does more than either peptide alone. No published clinical trial has tested the 12 mg/6 mg blend, so any benefit claim is extrapolated from single-peptide data.
- Tesamorelin: reduced visceral fat, improved waist circumference, and favorable lipid changes in HIV lipodystrophy trials.
- Ipamorelin: increased GH and IGF-1 in early studies, with minimal cortisol effect in animal models.
- Blend: no human outcome data published as of this writing.
Tesamorelin/Ipamorelin 8mg Blend and Other Ratios
The 12 mg/6 mg vial is one of several configurations sold by research suppliers. A tesamorelin ipamorelin 8mg blend usually contains 8 mg of tesamorelin with either 4 mg or 2 mg of ipamorelin.
| Label | Tesamorelin | Ipamorelin | Ratio | Total peptide |
|---|---|---|---|---|
| 12mg/6mg | 12 mg | 6 mg | 2:1 | 18 mg |
| 8mg blend (common) | 8 mg | 4 mg | 2:1 | 12 mg |
| 8mg blend (high tesamorelin) | 8 mg | 2 mg | 4:1 | 10 mg |
| 10mg/5mg | 10 mg | 5 mg | 2:1 | 15 mg |
| 5mg/5mg | 5 mg | 5 mg | 1:1 | 10 mg |
Higher tesamorelin ratios favor GHRH-driven GH release, while higher ipamorelin ratios favor ghrelin-receptor activity. The right configuration depends on the research question, not on marketing labels.
Dosage, Stacking, and Comparisons
No standard human dosage exists for a tesamorelin/ipamorelin 12 mg/6 mg blend. Published tesamorelin dosing in FDA trials was 1 mg or 2 mg injected subcutaneously once daily, and ipamorelin has been studied at roughly 100–300 mcg in small trials. Researchers who ask about tesamorelin aod9604 cjc1295 ipamorelin 12mg blend dosage are usually trying to map those single-peptide doses onto a combined vial, which is not a validated approach.
Typical Research Dosing Logic
- Reconstitute with bacteriostatic water according to vendor instructions.
- Calculate each peptide separately using the 2:1 ratio.
- Track GH, IGF-1, fasting glucose, and cortisol if the protocol requires it.
How It Compares to CJC-1295 Stacks
Many researchers compare cjc-1295 ipamorelin vs tesamorelin before choosing a GH secretagogue. CJC-1295 lasts much longer in circulation, while tesamorelin has the strongest human body-composition data.
A cjc 1295 ipamorelin tesamorelin stack would combine a long-acting GHRH analog with a short-acting one plus a ghrelin mimetic, which raises questions about receptor desensitization and overlapping GH pulses. No controlled study supports that three-peptide combination.
Fat-loss research also includes other molecules. People who read about aod 9604 mots c tesamorelin ipamorelin are usually comparing lipolytic fragments and mitochondrial peptides with GHRH blends, but those are separate research categories with different mechanisms.
Safety, Sourcing, and Legal Status
Tesamorelin is FDA-approved as Egrifta for HIV-associated lipodystrophy, but the 12 mg/6 mg blend is not. Ipamorelin has no FDA approval for any human indication.
Reported side effects of tesamorelin in trials include injection-site reactions, joint pain, and elevated IGF-1. Human safety data for ipamorelin remain limited, and combining peptides could add risks that have not been measured.
Research peptides are not regulated like prescription drugs. Purity, sterility, and actual peptide content vary by vendor, so a certificate of analysis matters more than a label claim. Anyone considering human use should talk to a licensed healthcare professional rather than self-dosing a research blend.
Frequently Asked Questions
What is tesamorelin/ipamorelin 12mg/6mg used for in research?
The blend is used in laboratory studies of growth hormone secretion, body composition, and fat metabolism. Tesamorelin has human trial data for visceral fat reduction in HIV lipodystrophy, while ipamorelin data are mostly preclinical. No published trial has tested the 12 mg/6 mg combination itself.
Is tesamorelin/ipamorelin 12mg/6mg FDA-approved?
No. Tesamorelin alone is FDA-approved as Egrifta for HIV-associated lipodystrophy, and ipamorelin is not FDA-approved for any human use. The 12 mg/6 mg blend is sold as a research chemical only and is not an approved drug product.
What is the difference between the 12mg/6mg and the 8mg blend?
The 12 mg/6 mg vial contains 12 mg tesamorelin and 6 mg ipamorelin, a 2:1 ratio. An 8 mg blend typically contains 8 mg tesamorelin with 4 mg or 2 mg ipamorelin, so the total peptide mass and ratio differ. Both are research products with no established human dosing.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.